Portal de Periódicos da CAPES

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

2019; Massachusetts Medical Society; Volume: 380; Issue: 20 Linguagem: Inglês

10.1056/nejmoa1813959

1533-4406

Hans‐Christoph Diener, Ralph L. Sacco, J. Donald Easton, Christopher B. Granger, Richard A. Bernstein, Shinichiro Uchiyama, Jörg Kreuzer, Lisa Cronin, Otto W. Witte, Claudia Grauer, Martina Brueckmann, M. A. Chernyatina, Geoffrey A. Donnan, José M. Ferro, Martin Grond, Bernd Kallmünzer, Jerzy Krupiński, Byung‐Chul Lee, Robin Lemmens, Jaime Masjuán, Miroslav Odinak, Jeffrey L. Saver, Peter D. Schellinger, Danilo Toni, Ḱazunori Toyoda,

Cardiac Imaging and Diagnostics

Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban is no more effective than aspirin in preventing recurrent stroke after a presumed embolic stroke from an undetermined source. Whether dabigatran would be effective in preventing recurrent strokes after this type of stroke was unclear.